Group 1 - The company has received the drug registration certificate for Pirfenidone Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][2] - The drug is classified as a Class 4 chemical drug and is indicated for the treatment of partial seizures in adults and children aged 4 years and above [2] - The original developer of the drug is Eisai Europe Limited, which first launched it in the EU in July 2012, followed by approvals in the US and Japan [2] Group 2 - The sales amount for the original drug in 2024 is projected to be approximately 96.52 million yuan, reflecting a year-on-year growth of 39.74% [2] - The company has entered into a commercial cooperation agreement with Anhui Wanbang Pharmaceutical Technology Co., Ltd., where Wanbang will handle sales and promotion of the drug [2] - The company is responsible for the production and supply of the drug and will share in the profits from sales after the drug is launched [2]

Core Viewpoint - Chengdu Easton Biopharmaceutical Co., Ltd. will participate in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, to enhance communication with investors regarding its operational results and financial indicators for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 16, 2025, from 15:00 to 17:00 [2]. - The location of the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [2][4]. - The format of the meeting will be an online interactive session [2][4]. Group 2: Participants and Interaction - Key participants include General Manager Yuan Mingxu, Board Secretary Li Shuyun, and Chief Financial Officer Bo Xiaoqin [2]. - Investors can participate online during the meeting and submit questions in advance from September 8 to September 15, 2025, by visiting the Roadshow Center or emailing the company [2][4]. Group 3: Contact Information - For inquiries, investors can contact the Securities Department at 028-86106668 or via email at ydsw@eastonpharma.cn [3].

证券代码：688513 证券简称：苑东生物 公告编号：2025-061 成都苑东生物制药股份有限公司 关于参加 2025 年半年度科创板创新药行业集体 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2025 年 8 月 19 日 发布公司 2025 年半年度报告，为加强与投资者的深入交流，使投资者更加全面、 深入地了解公司 2025 年半年度的经营成果、财务指标等情况，公司计划于 2025 年 9 月 16 日（星期二）下午 15:00-17:00 参加由上海证券交易所举办的 2025 年 半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 （一）会议召开时间：2025 年 9 月 16 日（星期二）下午 15:00-17 ...

成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关 情况公告如下： 一、药品基本情况 药品名称：吡仑帕奈片 证券代码：688513 证券简称：苑东生物 公告编号：2025-062 成都苑东生物制药股份有限公司 关于自愿披露吡仑帕奈片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 剂型：片剂 规格：4mg、2mg 注册分类：化学药品 4 类 药品有效期：12 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH21462025 受理号：CYHS2401346、CYHS2401347 证书编号：2025S02701、2025S02702 药品批准文号：国药准字 H20255313、国药准字 H20255314 审批结论： 特此公告。 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。质量标准、 ...

苑东生物公告，公司近日收到国家药品监督管理局核准签发的吡仑帕奈片药品注册证书。吡仑帕奈片主 要用于成人和4岁及以上儿童癫痫部分性发作患者的治疗。该药品为公司按化学药品4类注册申报，获批 后视同通过一致性评价。目前，该药品尚未实现销售，公司已与万邦医药签署合作协议，万邦医药负责 销售和推广，公司负责生产和供应并享有销售利润的部分分红权益。 ...

智通财经APP讯，苑东生物(688513.SH)发布公告，公司于近日收到国家药品监督管理局(简称"国家药监 局")核准签发的吡仑帕奈片《药品注册证书》。 吡仑帕奈片主要活性成份为吡仑帕奈，属于国家《麻醉药品和精神药品管理条例》规定的第二类精神药 品，适应症为用于成人和4岁及以上儿童癫痫部分性发作患者(伴有或不伴有继发全面性发作)的治疗。 ...

Company Overview - Yuan Dong Bio-pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On September 4, Yuan Dong Bio's stock fell by 5.42%, trading at 59.80 yuan per share, with a transaction volume of 86.87 million yuan and a turnover rate of 0.79%. The total market capitalization is 10.557 billion yuan [1] Fund Holdings - Tai Ping Fund has one fund heavily invested in Yuan Dong Bio. The Tai Ping Medical Innovation Mixed Fund A (021027) held 11,500 shares in the second quarter, accounting for 3.27% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 39,400 yuan [2] - The Tai Ping Medical Innovation Mixed Fund A (021027) was established on June 4, 2024, with a latest scale of 13.9827 million yuan. Year-to-date returns are 63.38%, ranking 349 out of 8,180 in its category; one-year returns are 58.77%, ranking 1,728 out of 7,978; and since inception returns are 57.25% [2]

Group 1 - The core viewpoint of the news is that Yuan Dong Bio has seen a significant increase in its stock price, with a rise of 5.08% to 66.20 CNY per share, and a total market capitalization of 11.686 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, specializes in the research, production, and sales of chemical raw materials and chemical drug formulations, with its main revenue sources being 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] - The company has a trading volume of 1.13 million CNY and a turnover rate of 1.00% as of the report date [1] Group 2 - The Hongde Medical Innovation Mixed Fund A (012481) holds a significant position in Yuan Dong Bio, with 27,000 shares, accounting for 7.84% of the fund's net value, making it the third-largest holding [2] - The fund has achieved a year-to-date return of 64.56% and a one-year return of 83.28%, ranking 294 out of 8180 and 684 out of 7967 respectively in its category [2] - The fund was established on February 22, 2023, with a current scale of 10.4748 million CNY [2]

Group 1 - In the first half of the year, A-share listed companies reported a total net profit attributable to shareholders of 2.99 trillion yuan, a year-on-year increase of 2.45%, with nearly 77% of stocks achieving profitability and about 46% showing positive net profit growth [2] - The agricultural, forestry, animal husbandry, fishery, steel, building materials, computer, and non-ferrous metals sectors experienced rapid performance growth, while the real estate sector showed significant losses [2] - BYD's new energy vehicle sales in August reached 373,600 units, slightly up from 373,100 units in the same month last year, with cumulative sales from January to August totaling 2.864 million units, representing a year-on-year growth of 23% [10] Group 2 - New energy vehicle manufacturers such as Leap Motor, Xpeng Motors, and NIO reported record monthly delivery numbers, while Li Auto experienced a decline in monthly deliveries for three consecutive months due to product transitions and adjustments in its sales and service system [5] - Longi Green Energy has invested in a storage company, Suzhou Jingkong Energy Technology Co., Ltd., and is in discussions to acquire another storage company [7] - Chengdu Huamei announced the release of a 4-channel 12-bit 40G high-precision RF direct sampling ADC chip and has received intention orders [9] Group 3 - Heng Rui Pharmaceutical announced that its innovative drug, Zemeituosita Tablets, has received conditional approval for market launch [8] - Yuan Dong Bio announced that its sodium nafamostat oral disintegrating tablets have obtained a drug registration certificate, making it the first domestic generic drug approved for market [11] - Guizhou Moutai announced that its controlling shareholder, Moutai Group, increased its stake by purchasing 67,821 shares, accounting for 0.0054% of the company's total share capital [12] Group 4 - Yonghui Supermarket announced an adjustment to its plan for issuing A-shares to specific targets, with the total fundraising amount adjusted to no more than 3.114 billion yuan [13] - Su Da Weige announced plans to acquire up to 51% of Changzhou Weipu's equity for no more than 510 million yuan [16] - The company Zongtai Auto announced that its subsidiary's assets are under compulsory execution, and it will not be able to resume production this year [15]

Group 1 - The core point of the article is that Yuandong Biologics has received approval from the National Medical Products Administration for the drug registration certificate of its product, Sodium Naphthylacetate Oral Disintegrating Tablets [2] Group 2 - The drug is named Sodium Naphthylacetate Oral Disintegrating Tablets, indicating a new addition to the company's product portfolio [2] - The announcement was made on the evening of September 1, highlighting the company's ongoing efforts in drug development and regulatory compliance [2]